COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias
- 25 May 2020
- journal article
- editorial
- Published by Elsevier BV in Heart Rhythm
- Vol. 17 (9), 1423-1424
- https://doi.org/10.1016/j.hrthm.2020.05.024
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Considerations for drug interactions on QTc interval in exploratory COVID-19 treatmentHeart Rhythm, 2020
- Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 InfectionCirculation: Arrhythmia and Electrophysiology, 2020
- Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)Mayo Clinic Proceedings, 2020
- A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical TrialJAMA Network Open, 2020
- The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/AzithromycinPublished by Cold Spring Harbor Laboratory ,2020
- SARS-CoV-2, COVID-19, and inherited arrhythmia syndromesHeart Rhythm, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJama-Journal Of The American Medical Association, 2020
- Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, ChinaJama-Journal Of The American Medical Association, 2020